Stock comparison
Ligand Pharmaceuticals
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LGND
Ligand Pharmaceuticals
Market cap
$4.6B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LGND | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 55D | 69B | MTD |
| Benjamin Graham | 67D | 65B | LGND |
| Philip Fisher | 64C | 63C | LGND |
| Peter Lynch | 54C | 66B | MTD |
| Joel Greenblatt | 53D | 68B | MTD |
| Charlie Munger | 57D | 74B | MTD |
| Terry Smith | 47D | 70B | MTD |
Side-by-side metrics
| Metric | LGND | MTD |
|---|---|---|
| Market cap | $4.6B | $22.29B |
| P/E (TTM) | 27.6x | 25.3x |
| EV/EBIT | 97.7x | 21.6x |
| ROIC (TTM) | 5.61% | 36.09% |
| Gross margin | 98.61% | 57.79% |
| Net margin | 55.95% | 21.4% |
| Revenue CAGR 5y | 2.64% | 2.01% |
| EPS CAGR 5y | 16.8% | 6.12% |
| Debt / Equity | 0.5x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LGND leads on
- EPS CAGR 5y16.8%vs 6.12%+64%
- Net margin55.95%vs 21.4%+62%
- Gross margin98.61%vs 57.79%+41%
- Revenue CAGR 5y2.64%vs 2.01%+24%
MTD leads on
- Debt / Equity-vs 0.5x+101%
- ROIC (TTM)36.09%vs 5.61%+84%
- Market cap$22.29Bvs $4.6B+79%
- EV/EBIT21.6xvs 97.7x+78%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.